ATS 2019 Virtual Final Program

P190 Significance and Predictive Factors of Recurrence in Anti-Aminoacyl-tRNA Synthetase Antibodies-Interstitial Lung Disease/ R. Takei, Y. Yamano, K. Kataoka, T. Yokoyama, T. Matsuda, T. Kimura, T. Johkoh, O. Takahashi, Y. Kondoh, Seto, Japan, p.A1443 P191 Staining Lung Tissue for Select Myositis Specific Antibodies in the Diagnosis of Rapidly Progressive Interstitial Lung Disease/ B. Short, C. Agerstrand, M. Sieglin, A. Saqi, N. Patel, New York, NY, p.A1444 P192 Acute Respiratory Failure in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease/ K. Koyama, N. Naitoh, K. Kagawa, H. Nishimura, H. Kawano, Y. Toyoda, H. Goto, M. Azuma, Y. Nishioka, Tokushima, Japan, p.A1445 P193 Rheumatoid Arthritis’ Clinical Characteristics Stratified by Interstitial Lung Disease Patterns/ C. de Assis Molina, M.L. Sabbag, M. Sawamura, K. Bonfiglioli, F.E. Arimura, C.R.R. Carvalho, R.A. Kairalla, L. Kawano-Dourado, Sao Paulo, Brazil, p.A1446 P194 The Design and Rationale of the Trail Trial: A Randomized Double-Blind Phase II Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease/ J. Solomon, Denver, CO, p.A1447 CLINICAL THEMATIC POSTER SESSION A38 IDIOPATHIC INTERSTITIAL PNEUMONIA: DIAGNOSIS AND NATURAL HISTORY 9:15 a.m. - 4:15 p.m. KBHCCD Area B (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitators : R. Raj, MD, Palo Alto, CA A. Suzuki, MD, Nagoya, Japan P196 Introducing Transbronchial Cryobiopsies in Diagnosing Diffuse Parenchymal Lung Diseases in Greece: Implementing Training into Clinical Practice/ M. Gaga, K. Samitas, L. Kolilekas, I. Vamvakaris, C. Gkogkou, P. Filippousis, E. Zervas, Athens, Greece, p.A1448 P197 On-Line Multidisciplinary Discussion on Interstitial Lung Diseases (ILD): Using New Technologies to Connect General Hospitals to Expert Units Managing ILD/ J.R. Francesqui Candela, M. Serrano, M. Benegas, E. Laserna, S. Cuerpo, F. Hernandez-Gonzalez, J. Vilaseca, M. Sanchez, J. Sellares Torres, Barcelona, Spain, p.A1449 P198 The Value of Fine Crackles on Chest Auscultation in the Early Diagnosis of Interstitial Lung Diseases/ T. Ritchie, S. Aldhaheri, O. Moran-Mendoza, Kingston, Canada, p.A1450 P199 Derivation and Validation of a Diagnostic Prediction Model for Interstitial Lung Disease/ J. Oldham, A. Kitich, J. Morisset, A.-C. Maynard-Paquette, S. Alqalyoobi, J.V. Pugashetti, D. Pritchard, N. Boctor, J. Graham, A. Kulinich, C. Mendez, E. Foster, E. Lafond, S.A. Choudhry, J. Chalaoui, M. Kadoch, Sacramento, CA, p.A1451 P200 Postinflammatory Pulmonary Fibrosis: Clarifying the Diagnosis/ A. Vu, M. Baqir, T. Moua, A. Vasireddy, J.H. Ryu, Rochester, MN, p.A1452 P201 Squawks in Interstitial Lung Diseases/ C.A.D Pereira, M.D.C. Castro, M.R. Soares, R. Boaventura, P. Gomes, A. Gimenez, C. Fukuda, M. Cerezoli, Sao Paulo, Brazil, p.A1453 P202 Identification of Predisposing Environmental Risk Factors for Interstitial Lung Disease/ C. Lee, A.O. Adegunsoye, J. Chung, R. Jablonski, I. Pan, S. Montner, R. Vij, M.E. Strek, Chicago, IL, p.A1454 P203 Diagnostic Role of Measurement of Asbestos Bodies in Bronchoalveolar Lavage Fluid in Patients with Interstitial Lung Diseases/ Y. Inagaki, C. Sugimoto, T. Teramoto, T. Kasai, M. Akira, T. Arai, S. Hayashi, Y. Inoue, Sakai, Japan, p.A1455 P204 Minimalist Thoracoscopic Biopsy of Interstitial Lung Disease/ E. Pompeo, A.G. Elkhouly, P. Rogliani, E. Puxeddu, F. Cavalli, M. Dauri, Rome, Italy, p.A1456 P205 The Diagnosis of Interstitial Lung Disease: Comparison Between HRTC Appearance and Histological Pattern/ G. Verri, F. Guerrera, P. Lyberis, P. Solidoro, L. Costardi, L. Mercante, G. Limerutti, L. Delsedime, M. Mangiapia, M.M. Bardessono, A. Mattei, P.L. Filosso, E. Ruffini, C. Albera, Turin, Italy, p.A1457 P206 Assessing Diagnostic Delays in Patients with Interstitial Lung Disease/ D. Pritchard, J.V. Pugashetti, R. Harper, B. Morrissey, J. Oldham, Sacramento, CA, p.A1458 P207 A Single-Center Prospective Cohort Study of Diagnostic Procedure of Interstitial Pneumonia in Clinical Setting; The Importance of Distinguishing Chronic Hypersensitivity Pneumonitis from Idiopathic Pulmonary Fibrosis/ M. Ishizuka, Y. Inoue, T. Honda, Y. Miyazaki, Tokyo, Japan, p.A1459 Facilitator : M.L. Salisbury, MD, Ann Arbor, MI P208 Changes in Lung Histopathology from Diagnosis to Transplant in IPF Patients/ A. Unterman, B. Pertzov, N. Kaminski, M.R. Kramer, New Haven, CT, p.A1460 P209 Atypical Explant Histopathology in Idiopathic Pulmonary Fibrosis and Severe Pulmonary Hypertension/ L. Sullivan, F. Shaikh, Z. Anklesaria, A.D. Yuen, R. Saggar, R.N. Channick, Los Angeles, CA, p.A1461 P210 Clinical Significance of Serum Adiponectin for Patients with Pulmonary Fibrosis/ Y. Fujiki, Tochigi Prefecture, Japan, p.A1462 P211 CA 15-3: A Novel Biomarker for the Diagnosis and Progression of Interstitial Lung Disease/ M. Bailey, K. Kato, K.S. Knox, B. Natt, S. Chaudhary, Tucson, AZ, p.A1463 P212 Diagnosing Interstitial Lung Diseases Using Exhalative Breath Markers/ E. Krauss, M. Brinkmeier, W. Seeger, F. Drakopanagiotakis, A. Guenther, Giessen, Germany, p.A1464 ATS 2019 • Dallas, TX SUNDAY • MAY 19 53 SUNDAY MORNING